Skip to main content
Menu
Revvity logo
Contact us

Loading...

US

Loading...

Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States
Login/Register here
Revvity web shop online account

Get exclusive pricing on all online purchases.

Login to your Revvity.com account for your account's pricing, easy re-ordering from favorites & order history, priority order processing, and dynamic order tracking.

Login Register
Revvity Omics portal accounts

Initiate a new order or access test status and results for clinical genomics or newborn screening services.

View login options
Breadcrumb
...
  • Home
  • Blog
  • Physiological Models
  • Rethinking Alzheimer’s disease with brain-on-chip technology.
organ1920x640

Blog

Physiological Models

May 13th 2025

2 min read

Rethinking Alzheimer’s disease with brain-on-chip technology.

Help us improve your Revvity blog experience!

Feedback

Neurogenerative diseases such as Alzheimer’s disease remain among the most difficult to study, with many clinical trials ending in failure and effective therapies remaining elusive. One reason for this is the lack of physiologically relevant models that can faithfully replicate the complexity of the human brain. Additionally, our understanding of the intricate pathology involved in neuronal degeneration is still evolving.

For many years, Alzheimer’s research has centered on the amyloid plaque hypothesis, which suggests that the accumulation of amyloid-beta plaques in the brain is a central driver of disease development. This has prompted widespread efforts to target these plaques. But even with the development of potent antibodies, clinical outcomes have been limited.

As the field evolves, attention is shifting toward other potential drivers of Alzheimer’s disease, particularly the role of soluble amyloid-beta oligomers.

The soluble amyloid-beta oligomer hypothesis

Emerging research suggests that at the very early stages of Alzheimer’s disease, soluble amyloid-beta oligomers start to accumulate in the brain, long before the formation of amyloid plaques. These oligomers are believed to be extremely toxic to neurons and other cell types within the brain, potentially leading to disease onset and progression. As a result, strategies to remove these oligomers or limit their toxicity are emerging as promising therapeutic avenues.

Exploring this theory requires the use of models that more accurately represent the cellular architecture and microenvironment of the human brain. While traditional 2D cultures and animal models have their place, they often fall short in their ability to translate findings into clinically relevant insights.

Next-generation modeling with brain-on-chip technology

Organ-on-chip systems have emerged as a compelling alternative, offering a more dynamic and physiologically relevant context for studying disease mechanisms and evaluating novel treatments. In particular, brain-on-chip devices integrate various human brain cell types—such as neurons, astrocytes, and endothelial cells—with compartmentalized microfluidic environments that mimic the brain’s structure and function. These systems allow researchers to model complex processes such as synaptic activity, neurotoxic spreading, and drug responses with greater accuracy than conventional models.

ETAP-Lab’s integrated approach

One company working at the forefront of this space is ETAP-Lab, a contract research organization with expertise in neurodegenerative disease modelling. Through a collaboration with microfluidics specialist NETRI, ETAP-Lab has developed brain-on-chip models tailored to major neurodegenerative conditions such as Alzheimer’s, Parkinson’s, and Amyotrophic Lateral Sclerosis.

At the core of this innovation is their method for producing stable misfolded tau oligomers (TauO) from recombinant full-length human tau protein. Unlike conventional approaches, this technique requires no chemical modification or helper proteins, resulting in highly physiologically relevant neurotoxins for disease modeling. The team utilizes Revvity’s Operetta™ CLS high-content analysis system to quantify cellular responses to neurotoxins and pharmacological treatments. By combining high-throughput screening methods and automated microscopy in a microplate format, they can assess the neurotrophic, neuroprotective, or neurotoxic effects of numerous chemical compounds in a controlled, reproducible, and automated manner.

If you’re interested in how ETAP-Lab is applying these innovations to better understand early neurodegenerative mechanisms—and what this could mean for future drug development—read our exclusive interview with ETAP-Lab’s CEO, Nicolas Violle.
 

Read case study


For research use only. Not for use in diagnostic procedures.

Help us improve your Revvity blog experience!

Feedback

Share this post:

  • Email
  • Facebook
  • Linkedin
  • Twitter

More Physiological Models posts

Essential characterization techniques for organoid cell models.
Read
Partnering with purpose: collaboration with Australian Organoid Facility.
Read
Revolutionizing drug safety: tools reshaping toxicology.
Read

Questions?
We’re here to help.

Contact us
Revvity Logo

©2025 Revvity - All rights reserved

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.